These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 9878996

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A benefit-risk assessment of sibutramine in the management of obesity.
    Nisoli E, Carruba MO.
    Drug Saf; 2003; 26(14):1027-48. PubMed ID: 14583064
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L, Fanghänel G, Yamamoto J, Martínez-Rivas L, Campos-Franco E, Berber A.
    Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Anti-obesity drugs: what does sibutramine offer? An analysis of its potential contribution to obesity treatment.
    Van Gaal LF, Wauters MA, De Leeuw IH.
    Exp Clin Endocrinol Diabetes; 1998 Sep; 106 Suppl 2():35-40. PubMed ID: 9792480
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study.
    Finer N, Bloom SR, Frost GS, Banks LM, Griffiths J.
    Diabetes Obes Metab; 2000 Apr; 2(2):105-12. PubMed ID: 11220522
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study.
    Hanotin C, Thomas F, Jones SP, Leutenegger E, Drouin P.
    Int J Obes Relat Metab Disord; 1998 Jan; 22(1):32-8. PubMed ID: 9481597
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action.
    Nisoli E, Carruba MO.
    Obes Rev; 2000 Oct; 1(2):127-39. PubMed ID: 12119986
    [Abstract] [Full Text] [Related]

  • 15. Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction.
    Zannad F, Gille B, Grentzinger A, Bruntz JF, Hammadi M, Boivin JM, Hanotin C, Igau B, Drouin P.
    Am Heart J; 2002 Sep; 144(3):508-15. PubMed ID: 12228789
    [Abstract] [Full Text] [Related]

  • 16. Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study.
    Mathus-Vliegen EM, Balance Study Group.
    Eur J Clin Nutr; 2005 Aug; 59 Suppl 1():S31-8; discussion S39. PubMed ID: 16052193
    [Abstract] [Full Text] [Related]

  • 17. Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients.
    Faria AN, Ribeiro Filho FF, Kohlmann NE, Gouvea Ferreira SR, Zanella MT.
    Diabetes Obes Metab; 2005 May; 7(3):246-53. PubMed ID: 15811141
    [Abstract] [Full Text] [Related]

  • 18. [Pharma-clinics. Medication of the month. Sibutramine (Reductil)].
    Scheen AJ.
    Rev Med Liege; 2001 Sep; 56(9):656-9. PubMed ID: 11702509
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.